Skip to main content
Premium Trial:

Request an Annual Quote

New Prototype Test

Researchers in France have developed a new nanobody-based test for SARS-CoV-2 that initial testing suggests may be highly accurate, the Guardian reports.

It adds that the prototype test, called CorDial-1, from researchers at the University of Lille and elsewhere relies on camelid nanobodies, which are immobilized on an electrode and serve as a sort of electrochemical biosensor. The nanobodies react to the presence of the SARS-CoV-2 spike protein, which changes the electrical current across the sensor, the Guardian says. It adds that the current change is then detected by a small device that can be attached to a smartphone. 

"You start your mobile phone, a signal will occur, and depending on the height of the signal, you can say if you're COVID positive or negative," Lille's Sabine Szunerits says, according to CBS Miami.

It adds that an initial analysis using 300 samples found the test to be 90 percent accurate and delivered results within 10 minutes, noting that the researchers are now conducting a larger three-month trial involving 1,000 people.

The Scan

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in in human genomic research, and more.

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.